

AMENDMENT

Please amend the application without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

In the Claims:

- 1-7. (Cancelled)
8. (Withdrawn) The method of claim 3, wherein the modulator of Notch signalling is an inhibitor of Notch signalling, and wherein TNF α expression is increased.
9. (Cancelled)
10. (Withdrawn) The method of claim 6, wherein the modulator of Notch signalling is an inhibitor of Notch signalling, and wherein IL-10 expression is reduced.
11. (Cancelled)
12. (Withdrawn) The method of claim 4, wherein the modulator of Notch signalling is an inhibitor of Notch signalling, and wherein IL-5 expression is increased.
13. (Cancelled)
14. (Withdrawn) The method of claim 5, wherein the modulator of Notch signalling is an inhibitor of Notch signalling, and wherein IL-13 expression is increased.
- 15-20. (Cancelled)
21. (Currently amended) A method for reducing a T help 2 (TH2) immune response in a subject in need thereof comprising (i) contacting a cell of the immune system with a modulator of Notch signalling to modify cytokine expression in the cell, wherein the modulator of Notch signalling comprises a protein or polypeptide comprising a Notch ligand Delta-Serrate-Lag2 (DSL) domain and at least one epidermal growth factor-like (EGF-like) domain; and (ii) administering said cell, in which cytokine expression is modified, to the subject to reduce the TH2 immune response in said subject.
22. (Currently amended) A method for reducing a T help 1 (TH1) immune response in a subject in need thereof comprising (i) contacting a cell of the immune system with a modulator of Notch signalling to modify cytokine expression in the cell, wherein the modulator of Notch signalling comprises a protein or polypeptide comprising a Notch ligand Delta-Serrate-Lag2 (DSL) domain and at least one epidermal growth factor-like (EGF-like) domain; and (ii)

administering said cell, in which cytokine expression is modified, to the subject to reduce the TH1 immune response in said subject.

23. (Currently amended) A method for treating inflammation, an inflammatory condition or an autoimmune condition, in a subject in need thereof, comprising (i) contacting a cell of the immune system with a modulator of Notch signalling to modify cytokine expression in the cell, wherein the modulator of Notch signalling comprises a protein or polypeptide comprising a Notch ligand Delta-Serrate-Lag2 (DSL) domain and at least one epidermal growth factor-like (EGF-like) domain; and (ii) administering said cell, in which cytokine expression is modified, to the subject to treat the inflammation, inflammatory condition, or autoimmune condition.

24. (Previously presented) The method of claim 23, wherein the modification of cytokine expression in the cell comprises reduction of tumor necrosis factor-alpha (TNF α) expression in the cell.

25. (Currently amended) A method for modifying cytokine expression in cells of the immune system of a patient in need thereof, comprising administering a modulator of Notch signalling to said patient to modify cytokine expression of said patient's cells *in vivo*, wherein the modulator of Notch signalling comprises a protein or polypeptide comprising a Notch ligand Delta-Serrate-Lag2 (DSL) domain and at least one epidermal growth factor-like (EGF-like) domain.

26. (Currently amended) A method for modifying cytokine expression in cells of the immune system of a patient in need thereof comprising (i) administering a modulator of Notch signalling to the cells of said subject *ex-vivo* to modify cytokine expression in said cells, wherein the modulator of Notch signalling comprises a protein or polypeptide comprising a Notch ligand Delta-Serrate-Lag2 (DSL) domain and at least one epidermal growth factor-like (EGF-like) domain; and (ii) administering said cells in which cytokine expression is modified to the subject.

27. (Currently amended) A method for treating a disease associated with excessive [[TNF α]] tumor necrosis factor-alpha (TNF α) production, excessive interleukin-5 (IL-5) production or excessive interleukin-13 (IL-13) production, in a subject in need thereof, comprising (i) contacting a cell of the immune system with a modulator of Notch signalling to modify cytokine expression in the cell, wherein the modulator of Notch signalling comprises a protein or polypeptide comprising a Notch ligand Delta-Serrate-Lag2 (DSL) domain and at least

one epidermal growth factor-like (EGF-like) domain; and (ii) administering said cell, in which cytokine expression is modified, to the subject to treat the disease associated with excessive TNF α production, excessive IL-5 production or excessive IL-13 production.

28. (Currently amended) A method for modifying cytokine expression in cells of the immune system comprising contacting a cell of the immune system with a modulator of Notch signalling to modify cytokine expression in the cells, wherein the modulator of Notch signalling comprises a protein or polypeptide comprising a Notch ligand Delta-Serrate-Lag2 (DSL) domain ~~or a polynucleotide sequence encoding the protein or polypeptide~~ and at least one epidermal growth factor-like (EGF-like) domain.

29. (Cancelled)

30. (Currently amended) The method of ~~claim 29~~ claim 28, wherein the DSL domain or EGF-like domain is from Delta or Jagged.

31. (Withdrawn) The method of claim 1, wherein the modulator of Notch signalling comprises a fusion protein comprising a segment of a Notch ligand extracellular domain and an immunoglobulin FC segment or a polynucleotide encoding said fusion protein.

32. (Withdrawn) The method of claim 1, wherein the modulator of Notch signalling comprises a Notch intracellular domain (Notch IC) or a polynucleotide sequence encoding a Notch IC.

33. (Currently amended) A method for reducing a ~~[[TH2]]~~ T help 2 (TH2) immune response in a subject in need thereof comprising administering a modulator of Notch signalling to the subject to modify cytokine expression in cells of the immune system of said subject to reduce the TH2 immune response in said subject, wherein the modulator of Notch signalling comprises a protein or polypeptide comprising a Notch ligand Delta-Serrate-Lag2 (DSL) domain and at least one epidermal growth factor-like (EGF-like) domain.

34. (Currently amended) A method for reducing a ~~[[TH1]]~~ T help 1 (TH1) immune response in a subject in need thereof comprising administering a modulator of Notch signalling to the subject to modify cytokine expression in cells of the immune system of said subject to reduce the TH1 immune response in said subject, wherein the modulator of Notch signalling comprises a protein or polypeptide comprising a Notch ligand Delta-Serrate-Lag2 (DSL) domain and at least one epidermal growth factor-like (EGF-like) domain.

35. (Currently amended) A method for treating inflammation, an inflammatory condition, or an autoimmune condition in a subject in need thereof, comprising administering a modulator of Notch signalling to the subject to modify cytokine expression in immune cells of said subject to treat inflammation, inflammatory condition, or autoimmune condition, wherein the modulator of Notch signalling comprises a protein or polypeptide comprising a Notch ligand Delta-Serrate-Lag2 (DSL) domain and at least one epidermal growth factor-like (EGF-like) domain.

36. (Currently amended) The method of claim 35, wherein the cytokine expression modification in the immune cells comprises reduction of ~~[[TNF α]]~~ tumor necrosis factor-alpha (TNF α) expression in the immune cells of said subject.

37. (Currently amended) A method for treating a disease associated with excessive TNF α production, excessive ~~[[IL-5]]~~ interleukin-5 (IL-5) production or excessive ~~[[IL-13]]~~ interleukin-13 (IL-13) production in a subject in need thereof, comprising administering a modulator of Notch signalling to the subject to modify cytokine expression in immune cells of said subject to treat the disease associated with excessive TNF α production, excessive IL-5 production or excessive IL-13 production, wherein the modulator of Notch signalling comprises a protein or polypeptide comprising a Notch ligand Delta-Serrate-Lag2 (DSL) domain and at least one epidermal growth factor-like (EGF-like) domain.

38. (Currently amended) The method of ~~claim 29~~ claim 28, wherein the DSL domain and EGF-like domain is from Delta or Jagged.